Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/23/21
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 02/15/24
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 04/30/15
End: 01/31/17
Due: 01/31/18
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | NCT04364620 | Alethia Biotherapeutics | user2@example.com | None | 2021-02-23 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |
| Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis | NCT06225843 | Alethia Biotherapeutics | user2@example.com | None | 2024-02-15 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |
| Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | NCT02412462 | Alethia Biotherapeutics | user2@example.com | None | 2015-04-30 | 2017-01-31 | 2018-01-31 | - | - | 2025-07-14 |